Miyako Nara1, Sakiko Ishihara1,2, Atsuko Kitano3, Nobuko Tamura4, Tomoyuki Aruga5, Daiki Kobayashi6, Seigo Nakamura7, Hideko Yamauchi8. 1. Department of Breast Surgery, Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-0021, Japan. 2. Department of Breast Surgery, Tokyo Medical and Dental University, Tokyo, Japan. 3. Department of Medical Oncology, St. Luke's International Hospital, Tokyo, Japan. 4. Department of Breast and Endocrine Surgery, Toranomon Hospital, Tokyo, Japan. 5. Department of Breast Surgery, Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-0021, Japan. aruga@cick.jp. 6. Department of General Internal Medicine, St. Luke's International Hospital, Tokyo, Japan. 7. Department of Breast Surgical Oncology, Showa University School of Medicine, Tokyo, Japan. 8. Department of Breast Surgical Oncology, St. Luke's International Hospital, Tokyo, Japan.
Abstract
BACKGROUND: Breast-conserving surgery (BCS) is often preferred for localized, small breast cancers, but its safety and efficacy in BRCA-mutation carriers is still controversial. This meta-analysis aimed to determine whether there was any significant difference in the incidence of ipsilateral breast tumor recurrence (IBTR) between BRCA-mutation carriers who underwent BCS and controls with sporadic breast cancer. METHODS: A PubMed search was conducted through March 2020 to identify studies examining the risk of IBTR after BCS in BRCA-mutation carriers versus controls. The Cochrane risk-of-bias tool was used to assess the risk of bias. The pooled risk ratio (RR) was calculated using the random-effects model. RESULTS: Thirteen studies involving 701 BRCA-mutation carriers and 4788 controls in total were eventually analyzed. In the meta-analysis, IBTR after BCS was significantly higher in BRCA-mutation carriers (RR: 1.589; 95% confidence interval (CI) 1.247-2.024; P < 0.001). Subgroup analysis of the follow-up time found that the RR for IBTR increased as the observation period lengthened (median follow-up: ≧ 7 years [RR: 1.505; 95% CI 1.184-1.913] and ≧ 10 years [RR: 1.601; 95% CI 1.201-2.132], respectively). However, a qualitative meta-analysis of overall survival in three cohort studies found no evidence to suggest a deterioration in overall survival in patients with BCS. CONCLUSIONS: The present study demonstrated that BRCA-mutation carriers with BCS have a higher risk of IBTR, which tended to persist for a long period and become more apparent with longer observation.
BACKGROUND: Breast-conserving surgery (BCS) is often preferred for localized, small breast cancers, but its safety and efficacy in BRCA-mutation carriers is still controversial. This meta-analysis aimed to determine whether there was any significant difference in the incidence of ipsilateral breast tumor recurrence (IBTR) between BRCA-mutation carriers who underwent BCS and controls with sporadic breast cancer. METHODS: A PubMed search was conducted through March 2020 to identify studies examining the risk of IBTR after BCS in BRCA-mutation carriers versus controls. The Cochrane risk-of-bias tool was used to assess the risk of bias. The pooled risk ratio (RR) was calculated using the random-effects model. RESULTS: Thirteen studies involving 701 BRCA-mutation carriers and 4788 controls in total were eventually analyzed. In the meta-analysis, IBTR after BCS was significantly higher in BRCA-mutation carriers (RR: 1.589; 95% confidence interval (CI) 1.247-2.024; P < 0.001). Subgroup analysis of the follow-up time found that the RR for IBTR increased as the observation period lengthened (median follow-up: ≧ 7 years [RR: 1.505; 95% CI 1.184-1.913] and ≧ 10 years [RR: 1.601; 95% CI 1.201-2.132], respectively). However, a qualitative meta-analysis of overall survival in three cohort studies found no evidence to suggest a deterioration in overall survival in patients with BCS. CONCLUSIONS: The present study demonstrated that BRCA-mutation carriers with BCS have a higher risk of IBTR, which tended to persist for a long period and become more apparent with longer observation.
Keywords:
BRCA-mutation carriers; Breast-conserving surgery; Hereditary breast and ovarian cancer syndrome; Ipsilateral breast tumor recurrence; Meta-analysis
Authors: Kathleen E Malone; Janet R Daling; David R Doody; Li Hsu; Leslie Bernstein; Ralph J Coates; Polly A Marchbanks; Michael S Simon; Jill A McDonald; Sandra A Norman; Brian L Strom; Ronald T Burkman; Giske Ursin; Dennis Deapen; Linda K Weiss; Suzanne Folger; Jennifer J Madeoy; Danielle M Friedrichsen; Nicola M Suter; Mariela C Humphrey; Robert Spirtas; Elaine A Ostrander Journal: Cancer Res Date: 2006-08-15 Impact factor: 12.701
Authors: D Ford; D F Easton; M Stratton; S Narod; D Goldgar; P Devilee; D T Bishop; B Weber; G Lenoir; J Chang-Claude; H Sobol; M D Teare; J Struewing; A Arason; S Scherneck; J Peto; T R Rebbeck; P Tonin; S Neuhausen; R Barkardottir; J Eyfjord; H Lynch; B A Ponder; S A Gayther; M Zelada-Hedman Journal: Am J Hum Genet Date: 1998-03 Impact factor: 11.025
Authors: Martin P Nilsson; Linda Hartman; Ulf Kristoffersson; Oskar T Johannsson; Ake Borg; Karin Henriksson; Elsa Lanke; Håkan Olsson; Niklas Loman Journal: Breast Cancer Res Treat Date: 2014-09-04 Impact factor: 4.872